

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/082,743	02/22/2002	Elias Humberto Hermida Ochoa	4696 EXAMINER	
26356	7590 11/04/2003			
ALCON RESEARCH, LTD.			KRISHNAN, GANAPATHY	
R&D COUNSEL, Q-148 6201 SOUTH FREEWAY			ART UNIT	PAPER NUMBER
•	FORT WORTH, TX 76134-2099		1623	
			DATE MAILED: 11/04/2003 (6	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
•					
Office Action Summary	10/082,743	HERMIDA OCHOA, ELIAS HUMBERTO			
•	Examiner	Art Unit			
The MAILING DATE of this communication an	Ganapathy Krishnan 1623 appears on the cover sheet with the correspondence address				
The MAILING DATE of this communication appropriate for Reply	pours on the botter sheet with the				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may a reply be till be within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON.	imely filed bys will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on					
2a) ☐ This action is FINAL . 2b) ☑ Th	nis action is non-final.				
3) Since this application is in condition for allow closed in accordance with the practice under	ance except for formal matters, p Ex parte Quayle, 1935 C.D. 11,	prosecution as to the merits is 453 O.G. 213.			
Disposition of Claims					
 4) ☐ Claim(s) 1-5 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 					
•	with from consideration.				
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-5</u> is/are rejected. 7)□ Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement				
Application Papers	or election requirement.				
9)☐ The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) acce		aminer.			
Applicant may not request that any objection to the					
11) The proposed drawing correction filed on					
If approved, corrected drawings are required in re	ply to this Office action.				
12) The oath or declaration is objected to by the Ex	kaminer.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority document	ts have been received.				
2. Certified copies of the priority document	ts have been received in Applicat	tion No			
3. Copies of the certified copies of the prio application from the International Bu * See the attached detailed Office action for a list	ıreau (PCT Rule 17.2(a)).				
14) Acknowledgment is made of a claim for domest	·				
a) The translation of the foreign language pro	ovisional application has been re	ceived.			
Attachment(s)	p 33 /=				
1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 1	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 10/082,743

Art Unit: 1623

DETAILED ACTION

The Amendment A (paper 15) filed August 25, 2003 has been received, entered into the record and carefully considered. The following information provided in the amendment affects the instant application:

- 1. Amendment to the specification.
- 2. Amendments to claims 1-5.
- 3. Remarks drawn to rejections under U.S.C.112 first, second paragraph.

Claims 1-5 are pending.

Claim Rejections - 35 USC § 112

The rejections of claims 1-5 under 35 USC 112, second paragraph have been overcome by amendments.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lindblad (US 4801619) in combination with Nocelli et al (EP 704216).

Application/Control Number: 10/082,743

Art Unit: 1623

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-5 are drawn to a method for treatment of mammalian joint exhibiting articular cartilage degeneration caused by osteoarthritis comprising implantation of a composition comprising 40mg of chondroitin sulfate and 30mg of sodium hyaluronate per cubic centimeter of aqueous vehicle; wherein the joint is a human joint selected from knees, shoulders, coxofemoral, ankles and elbows, intraphalangeal and wrists.

Lindblad drawn to treatment of inflammations of skeletal joints, teaches the intraarticular administration of hyaluronic acid or its salt as an aqueous solution. The amount administered is preferably in the range of 5 to 80mg (see col. 3, lines 35-53).

Nocelli et al drawn to compositions containing chondroitin sulfate, teach the use of the same for inflammatory processes of the cartilageous tissues, osteoarthritis, and articular inflammations in general. The compositions preferably contain 6 to 20 mg/kg/day (see page 4, lines 10-16). The compositions also contain water as the vehicle (see examples 1 and 2, page 4-5).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use a composition comprising sodium hyaluronate and chondroitin sulfate in a method for treating mammalian joint exhibiting articular cartilage degeneration with a

Page 4

Application/Control Number: 10/082,743

Art Unit: 1623

reasonable amount of success since the use of the compounds for the same purpose is seen to be disclosed for the treatment of articular cartilage degeneration and inflammatory processes of cartilaginous tissue individually in the prior art. The idea of combining them flows logically from their having been individually taught in prior art for the treatment of mammalian joint exhibiting articular cartilage degeneration.

One of ordinary skill in the art would be motivated to do so for the purpose of optimization of the amounts required for the method of treatment as instantly claimed.

Conclusion

1. Claims 1-5 are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathy Krishnan whose telephone number is 703-305-4837. The examiner can normally be reached on 8.30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 703-308-4624. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

GK

JAMES O. WILSON
JPERVISORY PATENT EXAMINER
JECHNOLOGY CENTER 1600